Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Apogee Therapeutics, Inc.NASDAQ: APGE
Short-term Debt · Q2 FY2026 · quarter ended Jun 2026
Short-term debt remains negative
Q2 FY2026 short-term debt was $0, compared with $4.03M a year earlier.
Context
- Short-term debt amounted to 0.0% of total assets at the end of Q2 FY2026, down 0.6 pp from a year earlier.
- Short-term debt increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term debt keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 3.23M | +193.7% |
| FY2023 | 2023-12-31 | 1.1M | — |
| FY2022 | 2022-12-31 | 0 | — |
Short-term Debt vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the 4th highest of 5, against a peer median of -16.3%.
- Short-term debt amounts to 0.0% of total assets for APGE, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.22B CNY | +58.9% | +33.8% | 30.8% |
| Jun 2026 | $238.1M USD | +36.4% | — | 22.2% | |
| Mar 2026 | $72M USD | — | — | 5.6% | |
| Sep 2026 | $44.1M USD | -69.1% | — | 2.6% | |
| Sep 2026 | $1.13M USD | — | — | 0.1% | |
| Jun 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | $0 USD | -100.0% | — | 0.0% | |
| Jun 2026 | $0 USD | — | -34.7% | 0.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding APGE) | — | -16.3% | -0.4% | 0.1% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.